The U.S. Food and Drug Administration (FDA) has approved Soleno Therapeutics’ extended-release formulation of diazoxide choline (DCCR) for easing…
Articles by Margarida Maia, PhD
Rhythm Pharmaceuticals plans to start a new Phase 2 clinical study in the first quarter of 2025 to test…
The U.S. Food and Drug Administration (FDA) will review Soleno Therapeutics’ application seeking approval of its extended-release formulation of…
Soleno Therapeutics is seeking approval of diazoxide choline controlled-release (DCCR) tablets in the U.S. for Prader-Willi syndrome (PWS)…
About every 10th person with Prader-Willi syndrome (PWS) experiences epilepsy or fever-induced seizures, and more likely so if the…
Harmony Biosciences has started a pivotal Phase 3 clinical trial testing pitolisant for excessive daytime sleepiness (EDS) and behavioral…
Acadia Pharmaceuticals has launched a Phase 3 clinical trial testing the safety and efficacy of ACP-101, an experimental carbetocin…
Providing needed care for someone with Prader-Willi syndrome (PWS) may make people — particularly those who serve as primary…
Too much insulin — a hormone that controls sugar in blood — may set off weight gain and excessive eating…
A boy was found to manifest “blended” symptoms of both Prader-Willi syndrome (PWS) and a form of hereditary spastic…